Beijing, China – From August 2nd to 5th, the China Heart Congress 2018 (CHC) 2018, the International Coronary Heart Disease Congress (ICC) and the 3rd Edition of the China Vessel Congress (CVC) were held at the China National Convention Center. Focused on the topic of "New Era, Heart Quest – Innovation·Transfer·Cooperation", CHC 2018 attracted many an expert in the field of cardiovascular disease from home and abroad, discussing the development, innovation and application of modern science and technology in the field of cardiovascular diseases with various perspectives and angles. Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), along with its subsidiaries of Shanghai MicroPort EP MedTech Co., Ltd., MicroPort Sorin CRM (Shanghai) Co., Ltd. and D-Pulse Medical (Beijing) Co., Ltd., took part in the congress.
On August 4, the satellite conference "Hands on Details, Strive for Milliseconds – China's Original Technology and Research Innovation" took place as scheduled. Professor Shubin Qiao of Fuwai Hospital of Chinese Academy of Medical Sciences, Professor Jinghua Liu of Beijing Anzhen Hospital, Professor Ling Tao from Xijing Hospital and Professor Xinkai Qu from Huadong Hospital were invited to co-chair the satellite conference. Professor Bo Xu of Fuwau Cardiovascular Hospital spoke about the innovation of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and Firesorb® Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb®"), which are independently developed by MicroPort®, before focusing on the latest clinical study results and relevant research data of the two products. The primary endpoint data at 12 months and QCA sub-study data at 13 months from the TARGET All-Comers ("TARGET AC") trial of Firehawk® in Europe proved that the world's lowest drug dosage coronary stent system needs only one-third dosage versus similar products while achieving the same efficacy with tremendously higher safety level. It not only facilitates the fast endothelialization of the vessels with shortened period of post-operative dual antiplatelet therapy, but is also likely to significantly reduce late adverse events and later burdens of medical expenses. The two-year clinical and angiography results of the first human trial (FUTURE-I) of Firesorb® showed that the occurrence of the main endpoint in two years is zero, the occurrence of patient-oriented composite endpoint ("PoCE"), including death, myocardial infarction, and revascularization is 2.2%, and the occurrence of all-cause mortality, target vessel MI and stent thrombosis are all zero, which fully demonstrated the safety and efficacy of Firesorb®. Professor Xu said that the development from Firehawk® to Firesorb® witnesses the progress of China's original technology, which is also one important aspect of that fact that China has started to master the core technologies in the area of high-end medical devices. In addition, MicroPort® invited Professor Kefei Dou from Fuwai Hospital to introduce the complications related to radiography guide wire in radial artery intervention and its solutions, and the Guide Wire of FireDragon™ Contrast Radiography. Professor Dou said FireDragon™ Guide Wire adopts unique design with outstanding crossability and extremely high safety.
At the congress, the MicroPort® booth demonstrated with a focus on "20 Years of MicroPort®" the development of all its businesses under the diversification strategy since its foundation 20 years ago, and showed its products in the segments of interventional cardiovascular, electrophysiology, cardiac rhythm management and surgical management. In addition, MicroPort® introduced a mobile phone APP applying augmented reality technology (AR), which enabled the users to learn about the development of MicroPort® coronary interventional products, the characteristics of Firehawk® and its unique target drug-eluting concept in a more immediate and clearer way after using the App to scan the Firehawk® QR code. The new experience was well received among the experts in attendance, who agreed that new type of demonstration should be promoted.
With the participation in the congress, MicroPort® comprehensively demonstrated several innovative achievements in the field of interventional cardiology, so as to provide the patients with safe, effective, and best, yet affordable, integrated solutions for interventional cardiology. As a leading innovation-driven high-end medical device group from China following the management credo of "Eyes for Greatness, Hands on Details", MicroPort® integrates the pursuit of details and the perseverance in innovation into its corporate gene, in addition to the emphasis on people. The MicroPort® employees always hold the belief that they should serve the patients and the doctors who also serve the patients eventually. They devote themselves into a common destiny with the patients and doctors, so as to mitigate and even eliminate the severe threats posed by various kinds of chronic diseases to human lives, and to play an increasingly important and even indispensable role while raising the average human life expectancy in good health to 100, 120, or even 150 years. As a company, MicroPort® will meet the unending demand for health and longevity in extending patient lives.